The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | 10-year follow-up in smoldering myeloma treated with len + dex
Maria Victoria-Mateos
• 1 Jun 2020
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the ten-year follow-up for a Phase II trial in smoldering myeloma at high-risk of progression to myeloma, outlining the sustained time to progression and overall survival benefit with lenalidomide (len) and dexamethasone (dex) versus no treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
